XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

28.06

Bid

12.34

Ask

31.99

Volume

0.00 Day's Range 0.00

13.48 52 Week Range 29.00

Market Cap

326.578M

Previous Close

28.06

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

19,784

Shares Outstanding

11,638,553

Dividend Yield

PE Ratio

-8.00

Earnings Per Share (EPS)

-3.51

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $28.06. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 29.00.

XOMA Royalty currently has 11,638,553 shares outstanding. The market capitalization of XOMA Royalty is $326.58 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -8.00.

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.06	3.92592592593	27	29	25.46	29519	27.86176589	CS
4	3.56	14.5306122449	24.5	29	21.86	33676	25.11062056	CS
12	2.49	9.7379741885	25.57	29	21.27	19784	25.00201031	CS
26	8.56	43.8974358974	19.5	29	18.95	19214	24.30896706	CS
52	11.92	73.85377943	16.14	29	13.48	22350	20.08761727	CS
156	-4.64	-14.1896024465	32.7	37.5	13.48	29475	20.7468591	CS
260	9.06	47.6842105263	19	46.32	13.48	37003	23.84549576	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NCPLNetcapital Inc	$ 0.1477 (42.02%)	1.31M
RRRichtech Robotics Inc	$ 2.00 (36.05%)	815.18k
CISOCISO Global Inc	$ 0.7957 (33.73%)	78.93k
SERVServe Robotics Inc	$ 9.69 (28.34%)	469.51k
ULYUrgent ly Inc	$ 1.90 (27.52%)	5
XCURExicure Inc	$ 0.3913 (-26.87%)	19.01k
PRTGPortage Biotech Inc	$ 0.197 (-14.01%)	28.02k
SANASana Biotechnology Inc	$ 5.05 (-12.93%)	10
RYAAYRyanair Holdings PLC	$ 101.12 (-11.55%)	1.19k
ONCOOnconetix Inc	$ 0.155 (-8.82%)	23.98k
NCPLNetcapital Inc	$ 0.1477 (42.02%)	1.31M
RRRichtech Robotics Inc	$ 2.00 (36.05%)	815.18k
SERVServe Robotics Inc	$ 9.69 (28.34%)	469.51k
SQQQProShares UltraPro Short QQQ	$ 8.34 (-1.42%)	356.67k
MAXNMaxeon Solar Technologies Ltd	$ 0.222 (2.97%)	215.03k